Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Crit Rev Eukaryot Gene Expr ; 32(2): 39-46, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35381130

RESUMEN

Long noncoding RNA (lncRNA) KTN1 antisense RNA 1 (KTN1-AS1) has been characterized as an oncogenic lncRNA in liver cancer. In this study, we investigated the functions of KTN1-AS1 in non-small-cell lung cancer (NSCLC). A total of 66 patients (27 females and 39 males, 28 to 67 years old, mean age 47.1 ± 6.6 years) with NSCLC were enrolled in this study. KTN1-AS1 and CDK1 expression in tissue samples of NSCLC patients were analyzed using reverse transcription quantitative polymerase chain reaction (RT-qPCR). Cell cycle progression assay and cell proliferation assay were performed to analyze the role of KTN1-AS1 in cell cycle progression and cell proliferation. RT-qPCR and Western blot analyses of cells with overexpression were performed to analyze the role of KTN1-AS1 in CDK1 expression. KTN1-AS1 was upregulated in NSCLC tissues and its expression level was positive correlated with CDK1 expression. KTN1-AS1 expression was not changed with clinical stages increasing, and higher KTN1-AS1 levels were associated with poor survival of NSCLC patients. KTN1-AS1 silencing induced G1 phase cell cycle arrest of NSCLC cells and downregulated CDK1. Moreover, KTN1-AS1 silencing suppressed NSCLC cell proliferation and CDK1 overexpression attenuated the effects of KTN1-AS1 silencing on cell proliferation. KTN1-AS1 may regulate cell cycle progression in NSCLC by regulating CDK1.


Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas , Neoplasias Pulmonares , ARN Largo no Codificante , Adulto , Anciano , Carcinoma de Pulmón de Células no Pequeñas/genética , Carcinoma de Pulmón de Células no Pequeñas/metabolismo , Línea Celular Tumoral , Proliferación Celular/genética , Femenino , Regulación Neoplásica de la Expresión Génica , Humanos , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/metabolismo , Masculino , Proteínas de la Membrana/genética , Persona de Mediana Edad , ARN Largo no Codificante/genética
2.
J Clin Lab Anal ; 36(11): e24662, 2022 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-36181310

RESUMEN

BACKGROUND: GRAP2 is an adaptor protein involved in leukocyte signal activation; however, the prognostic value of GRAP2 and its correlation with immune infiltration in lung adenocarcinoma (LUAD) are unclear. METHODS: Original data were downloaded from the TCGA database and Gene Expression Omnibus (GEO) database. GRAP2 expression was analyzed with the TCGA and TIMER databases. We evaluated the influence of GRAP2 on clinical prognosis using the Kaplan-Meier plotter, GEO, and GEPIA database. The TIMER and TISIDB databases were used to investigate correlations between GRAP2 expression and cancer immune characteristics. Finally, we confirmed the expression of GRAP2 in LUAD by immunohistochemistry staining. RESULTS: The transcription levels of GRAP2 were significantly lower in several human cancer types, including LUAD, than in adjacent normal tissues. Immunohistochemistry staining confirmed that LUAD tumor tissues had lower GRAP2 protein expression levels than adjacent normal tissues. GRAP2 downregulation was associated with poorer overall survival, pathologic stage, T stage, N stage, and primary therapy outcome in LUAD. Mechanistically, we found a hub gene set that included a total of 91 genes coexpressed with GRAP2, which were closely related to the immune response in LUAD. The expression levels of GRAP2 were positively correlated with the infiltration levels of multiple immune cells and the cumulative survival time of a few immune cells. GRAP2 expression was found to be positively correlated with that of multiple immune markers, chemokines, chemokine receptors, and MHC molecules in LUAD. CONCLUSIONS: GRAP2 can be used as a biomarker for assessing prognosis and immune infiltration levels in LUAD.


Asunto(s)
Adenocarcinoma del Pulmón , Neoplasias Pulmonares , Humanos , Pronóstico , Neoplasias Pulmonares/patología , Regulación Neoplásica de la Expresión Génica , Adenocarcinoma del Pulmón/patología , Biomarcadores
3.
J Recept Signal Transduct Res ; 40(6): 541-549, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-32515250

RESUMEN

Context: Curcumin has shown efficacy in promoting radiosensitivity combined with radiotherapy. However, the role and mechanism of curcumin on radiosensitivity in laryngeal squamous cell cancer (LSCC) is largely unknown.Objective: The aim of our study is to explore the role of IKKγ-NF-κB signaling in curcumin enhancing LSCC cell radiosensitivity in vitro.Materials and methods: Curcumin and X-ray were used to induce cell DNA damage and apoptosis, or inhibit cell clone formation. IKKγ siRNA and plasmid were used to change IKKγ expression. The CCK8 assay was used to detect cell viability. Clone formation ability was analyzed using a clonogenic assay, cell apoptosis was examined using flow cytometry, an immunofluorescence assay was used to detect DNA damage, while mRNA and protein levels were assayed using real time PCR and western blotting, respectively.Results: Curcumin significantly enhanced irradiation-induced DNA damage and apoptosis, while weakening clone-forming abilities of LSCC cell line Hep2 and Hep2-max. Compared to Hep2 cells, Hep2-max cells are more sensitive to curcumin post-irradiation. Curcumin suppressed irradiation-induced NF-κB activation by suppressing IKKγ expression, but not IKKα and IKKß. Overexpression of IKKγ decreased irradiation-induced DNA damage and apoptosis, while promoting clone-forming abilities of Hep2 and Hep2-max cells. IKKγ overexpression further increased expression of NF-κB downstream genes, Bcl-XL, Bcl-2, and cyclin D1. Conversely, IKKγ silencing enhanced irradiation-induced DNA damage and apoptosis, but promoted clone formation in Hep2 and Hep2-max cells. Additionally, IKKγ silencing inhibited expression of Bcl-XL, Bcl-2, and cyclin D1.Conclusions: Curcumin enhances LSCC radiosensitivity via NF-ΚB inhibition by suppressing IKKγ expression.


Asunto(s)
Carcinoma de Células Escamosas/radioterapia , Curcumina/farmacología , Quinasa I-kappa B/antagonistas & inhibidores , Neoplasias Laríngeas/radioterapia , FN-kappa B/antagonistas & inhibidores , Tolerancia a Radiación/efectos de los fármacos , Fármacos Sensibilizantes a Radiaciones/farmacología , Antineoplásicos/farmacología , Apoptosis , Biomarcadores de Tumor/genética , Biomarcadores de Tumor/metabolismo , Carcinoma de Células Escamosas/tratamiento farmacológico , Carcinoma de Células Escamosas/metabolismo , Carcinoma de Células Escamosas/patología , Proliferación Celular , Regulación Neoplásica de la Expresión Génica , Humanos , Neoplasias Laríngeas/tratamiento farmacológico , Neoplasias Laríngeas/metabolismo , Neoplasias Laríngeas/patología , Fosforilación , Transducción de Señal , Células Tumorales Cultivadas
4.
BMC Pulm Med ; 20(1): 273, 2020 Oct 20.
Artículo en Inglés | MEDLINE | ID: mdl-33081752

RESUMEN

BACKGROUND: LncRNA SNHG10 has been reported to be an oncogenic lncRNA in liver cancer. However, its roles in non-small cell lung cancer (NSCLC) remains unknown. METHODS: Tumor and paired non-tumor tissues were harvested from 62 NSCLC patients. RT-qPCR was used to detect the expression of SNHG10 and miR-21 in tissues. Overexpression experiments were used to evaluate the interaction between SNHG10 and miR-21 in NSCLC cells. CCK-8 assay was used to detect the cell proliferation. RESULTS: We observed the expression of SNHG10 was down-regulated in non-small cell lung cancer (NSCLC) compared with that in non-tumor tissues. Moreover, we found that high expression levels of SNHG10 predicted favorable survival of NSCLC patients, and the expression of miR-21 were increased in NSCLC and inversely correlated with SNHG10 expression. In NSCLC cells, overexpression of SNHG10 resulted in increased miR-21 gene methylation and decreased miR-21 expression. Moreover, overexpression of SNHG10 attenuated the enhancing effect of miR-21 overexpression on cell proliferation. CONCLUSIONS: SNHG10 may involve in NSCLC cell proliferation by regulating the miR-21 gene methylation.


Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/genética , Neoplasias Pulmonares/genética , MicroARNs/genética , MicroARNs/metabolismo , ARN Largo no Codificante/fisiología , Carcinoma de Pulmón de Células no Pequeñas/mortalidad , Carcinoma de Pulmón de Células no Pequeñas/patología , Proliferación Celular/genética , Regulación hacia Abajo , Humanos , Modelos Lineales , Neoplasias Pulmonares/mortalidad , Neoplasias Pulmonares/patología , Metilación , ARN Largo no Codificante/uso terapéutico , Células Tumorales Cultivadas
5.
J Cancer ; 12(15): 4638-4647, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34149927

RESUMEN

Cervical cancer is one of the most common malignant tumors in the female reproductive system. Radioresistance remains a significant factor that limits the efficacy of radiotherapy for cervical cancer. Interleukin-11 (IL-11) has been reported to be upregulated in various types of human cancer and correlate with clinical stage and poor survival. However, the exact effects and mechanisms of IL-11 in the radioresistance of cervical cancer have not yet been defined. In this research, TCGA databases revealed that IL-11 expression was upregulated in cervical cancer tissues and was associated with clinical stages and poor prognosis in cervical cancer patients. We discovered that IL-11 concentration was significantly upregulated in radioresistant cervical cancer cells. Knocking down IL-11 in Hela cells could reduce clonogenic survival rate, decrease cell viability, induce G2/M phase block, and facilitate cell apoptosis. In contrast, Exogeneous IL-11 in C33A cells could upregulate clonogenic survival rate, increase cell viability, curb G2/M phase block, and cell apoptosis. Mechanistic investigations showed that radioresistance conferred by IL-11 was attributed to the activation of the PI3K/Akt signaling pathway. Altogether, our results demonstrate that IL-11 might be involved in radioresistance, and IL-11 may be a potent radiosensitization target for cervical cancer therapy.

6.
Artículo en Inglés | MEDLINE | ID: mdl-24311863

RESUMEN

The objective of this paper was to investigate the antitumour mechanism of action of matrine by studying its inhibitory effect on gastric cancer SGC-7901 cells. SGC-7901 cells were chosen, and cell-killing capacity of matrine on gastric cancer SGC-7901 cells was determined using MTT assay and single PI staining assay. The results showed that matrine had an inhibitory effect on gastric cancer SGC-7901 cells, which was somewhat dose-dependent. The study concluded that matrine has a significant in-vitro inhibitory effect on SGC-7901 tumour cells, influences cell cycle of SGC-7901 cells, and induces their apoptosis.


Asunto(s)
Adenocarcinoma , Alcaloides/farmacología , Antineoplásicos Fitogénicos/farmacología , Apoptosis/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Medicamentos Herbarios Chinos/farmacología , Quinolizinas/farmacología , Neoplasias Gástricas , Animales , Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Ensayos de Selección de Medicamentos Antitumorales , Humanos , Ratones , Fitoterapia , Sophora , Matrinas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA